Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT02252796
Official study title

Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

Study summary

This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedHypofractionated Stereotactic Boost and Carboplatin

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 30, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?West Virginia University

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
West Virginia University
Interventions being studied
Radiation: Hypofractionated Stereotactic Boost; Drug: Carboplatin; Drug: Paclitaxel; Radiation: Image-guided IMRT
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Stage II - III Non Small Cell Lung Cancer

Reasons someone may not be able to joinExclusion criteria
  • Primary tumor directly invading into any mediastinal structures, such as the heart, major blood vessels, esophagus, trachea, and the proximal bronchial tree.
  • Prior chemotherapy for NSCLC
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
  • Severe, active co-morbidity
  • Pregnancy or women of childbearing potential
  • Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin
  • Uncontrolled neuropathy ≥ grade 2.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • West Virginia University Hospitals Mary Babb Randolph Cancer CenterMorgantown, West Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 30, 2018. Always confirm current availability with the study team.

View original record ↗